A Phase 2, Randomised, Double-Blind, Placebo-Controlled, Multicentre, Prospective Study to Assess Efficacy of Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy With High Preoperative Pulmonary Vascular Resistance
Phase of Trial: Phase II
Latest Information Update: 12 May 2019
Price : $35 *
At a glance
- Drugs Riociguat (Primary)
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms PEA Bridging Study
- 12 Sep 2018 Status changed from not yet recruiting to recruiting.
- 31 Aug 2018 Biomarkers information updated
- 04 Jul 2018 Planned End Date changed from 1 Feb 2020 to 1 Jul 2020.